Discovery and development of purine-scaffold Hsp90 inhibitors

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2008-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1517/17460441.3.1.99PMID 23480142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Crystal Structure of 6,7-Dihydro-5a,7a,13,14-tetraaza-pentaphene-5,8-dione

  2019cited by this paper
• Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.

  2008cited by this paper
• Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

  2007cited by this paper
• The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.

  2007influential reference
• NVP-AUY922 / VER-52296: A novel 3,4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design

  2007cited by this paper
• Expressed as the sole Hsp90 of yeast, the α and β isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor radicicol

  2007cited by this paper
• Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

  2007cited by this paper
• Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

  2007influential reference
• Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells

  2007influential reference
• Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies

  2007cited by this paper
• Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.

  2007cited by this paper
• Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.

  2007cited by this paper
• BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

  2006cited by this paper
• Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

  2006cited by this paper
• Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.

  2006cited by this paper
• Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors.

  2006cited by this paper
• Discovery and development of purine-scaffold Hsp90 inhibitors.

  2006cited by this paper
• Orally active purine-based inhibitors of the heat shock protein 90.

  2006influential reference
• Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

  2006influential reference
• 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.

  2006influential reference
• Basal-like breast carcinomas: clinical outcome and response to chemotherapy

  2006cited by this paper
• Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications.

  2006cited by this paper
• Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

  2006cited by this paper
• Management of small cell lung cancer

  2006cited by this paper
• Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

  2006cited by this paper
• Discovery and development of pyrazole-scaffold Hsp90 inhibitors.

  2006cited by this paper
• Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

  2006cited by this paper
• The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.

  2005cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005influential reference
• Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

  2005cited by this paper
• In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

  2005cited by this paper
• Phosphorylated tau and the neurodegenerative foldopathies.

  2005cited by this paper
• Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

  2005cited by this paper
• Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

  2005cited by this paper
• Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

  2005cited by this paper
• 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration

  2005cited by this paper
• The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

  2005cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

  2005cited by this paper
• Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

  2004cited by this paper
• Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.

  2004cited by this paper
• Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

  2004cited by this paper
• Hsp90 isoforms: functions, expression and clinical importance

  2004cited by this paper
• Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

  2004cited by this paper
• Therapeutic and diagnostic implications of Hsp90 activation

  2004influential reference
• Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness

  2004cited by this paper
• Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG

  2003cited by this paper
• A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

  2003cited by this paper
• Development of radicicol analogues.

  2003cited by this paper
• Structure and functional relationships of Hsp90.

  2003cited by this paper
• ATPases as drug targets: learning from their structure

  2002cited by this paper
• Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

  2002cited by this paper
• A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

  2001cited by this paper
• The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins

  2000cited by this paper
• Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.

  2000influential reference
• Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.

  1999cited by this paper
• Management of small cell lung cancer.

  1999cited by this paper
• DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

  1999influential reference
• Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.

  1998cited by this paper
• The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

  1998cited by this paper
• Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

  1997cited by this paper
• Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin*

  1996cited by this paper
• Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.

  1996cited by this paper
• p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

  1996cited by this paper
• Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.

  1992cited by this paper

• Advances in the structures, mechanisms and targeting of molecular chaperones

  2025cites this paper
• HSP90 inhibitors beyond oncology: optimization and mechanism insights in non-oncological diseases.

  2025cites this paper
• Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage

  2024cites this paper
• PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond

  2024cites this paper
• Potential Telomere-Related Pharmacological Targets.

  2020cites this paper
• Dynamically Shaping Chaperones. Allosteric Modulators of HSP90 Family as Regulatory Tools of Cell Metabolism in Neoplastic Progression

  2020cites this paper
• C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.

  2019cites this paper
• First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

  2018cites this paper
• BIIB021: A novel inhibitor to heat shock protein 90–addicted oncology

  2017cites this paper
• Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

  2017cites this paper
• The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

  2016cites this paper
• Natural Product Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis.

  2016cites this paper
• Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.

  2015cites this paper
• An Efficient Synthesis of Bis-Purine Derivatives by a PPh3-catalysed Double Addition of Dialkylated Xanthine Derivatives to Alkyl Propiolates

  2015cites this paper
• Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity

  2014cites this paper
• Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.

  2014cites this paper
• Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma

  2014cites this paper
• Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.

  2014cites this paper
• PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

  2013cites this paper
• Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

  2013cites this paper
• The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.

  2013cites this paper
• Design et synthèse d'une chimiothèque de cyclopeptides et d'analogues de la Shepherdine pour l'inhibition de l'interaction HSP90-Survivine

  2013cites this paper
• Microwave-assisted chemistry of purines and xanthines. An overview

  2013cites this paper
• Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects

  2012cites this paper
• Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors

  2012cites this paper
• The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

  2012cites this paper
• Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer

  2012influential citation
• Hsp90: structure and function.

  2012cites this paper
• HSP60 as a drug target.

  2012cites this paper
• Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors

  2012cites this paper
• Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010

  2011cites this paper
• Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.

  2011influential citation
• Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation

  2011cites this paper
• Heat Shock Protein as Molecular Targets for Breast Cancer Therapeutics

  2011cites this paper
• Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods

  2011cites this paper
• Many pharmaceutical companies are sponsoring clinical trials of inhibitors of HSP 90 ATPase

  2010influential citation
• Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.

  2010cites this paper
• ATPase inhibitors of heat-shock protein 90, second season.

  2010cites this paper
• Inhibition of HSP90 with Pochoximes: SAR and Structure‐Based Insights

  2009cites this paper
• Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.

  2009cites this paper
• To fold or not to fold: modulation and consequences of Hsp90 inhibition.

  2009cites this paper
• Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

  2009cites this paper
• A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas

  2009cites this paper
• Effectiveness of 17DMAG, a Geldanamycin Derivative, in Murine Acute Myeloid Leukemia

  2009cites this paper
• Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines.

  2009cites this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cites this paper
• New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

  2009influential citation
• Hsp90 inhibition with resorcyclic acid lactones (RALs).

  2009cites this paper
• Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.

  2009cites this paper
• Biological and chemical approaches to diseases of proteostasis deficiency.

  2009cites this paper
• Targeting Hsp90: small-molecule inhibitors and their clinical development.

  2008cites this paper
• Preparation of a set of 4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-4-ones as potential Hsp90 ligands

  2008cites this paper
• Development and application of Hsp90 inhibitors.

  2008cites this paper
• Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?

  2008cites this paper
• Practical synthesis of novel purine analogues as Hsp90 inhibitors

  2008cites this paper
• Medicinal chemistry of Hsp90 inhibitors.

  2008cites this paper
• Drugging the Cancer Chaperone HSP90

  2007cites this paper
• Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

  2007cites this paper